登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002653 证券简称：海思科 公告编号：2026-017 海思科医药集团股份有限公司 第五届董事会第三十六次会议 决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 表决结果：4票同意、0票弃权、0票反对 关联董事王俊民先生回避表决，公司独立董事对该事项进行了事前审议。 公司拟与海利克斯（成都）医药科技有限公司（以下简称"海利克斯"）共同投资9,700万元人民币设立 子公司海思生物科技有限责任公司（拟用名称，以工商登记为准，以下简称"海思生物"）,其中公司投 资8,700万元人民币，占海思生物股权比例89.69%，海利克斯投资1,000万元人民币，占海思生物股权比 例10.31%； 公司拟与海利克斯共同投资4,850万元人民币设立子公司海思新元医药科技有限责任公司（拟用名称， 以工商登记为准，以下简称"海思新元"）,其中公司投资4,350万元人民币，占海思新元股权比例 89.69%，海利克斯投资500万元人民币，占海思新元股权比例10.31%。 详见同日刊登在巨潮资讯网等公司指定信息披露媒体的 ...

Core Viewpoint - The company has approved an employee stock ownership plan (ESOP) aimed at enhancing employee engagement and aligning their interests with shareholders through stock ownership [1][2]. Group 1: Employee Stock Ownership Plan Approval - The company held a board meeting on December 12, 2024, and a shareholder meeting on December 30, 2024, to approve the ESOP and related management measures [1]. - The board authorized the management to handle matters related to the ESOP implementation [1]. Group 2: Stock Buyback Details - The company plans to repurchase between 7 million and 13.5 million shares of its A-shares, with a maximum buyback price of 9.80 yuan per share, totaling up to 132.3 million yuan [2]. - The actual buyback completed was 10,396,000 shares, costing approximately 69.99 million yuan [2]. Group 3: Fundraising and Subscription Details - The ESOP aims to raise a total of up to 46.68 million yuan, with a subscription price of 4.49 yuan per share, allowing for the purchase of up to 10.396 million shares [4]. - The actual funds raised amounted to 31.74 million yuan, with 29 employees participating in the subscription [4]. Group 4: Share Transfer and Accounting - As of February 12, 2026, 7,070,000 shares were transferred to the ESOP account, representing 1.393% of the company's total share capital [5]. - The company will follow accounting standards for share-based payments to assess the impact of the ESOP on its financial results [7]. Group 5: Independence and Governance - The first major shareholder did not participate in the ESOP, ensuring no conflict of interest [6]. - The ESOP holders are independent from the company's major shareholders and management, with a governance structure that prevents any single holder from exerting significant influence [6].

浙江京新药业股份有限公司（以下简称"公司"）已于2026年2月11日向香港联合交易所有限公司（以下 简称"香港联交所"）递交了发行境外上市股份（H股）并在香港联交所主板挂牌上市（以下简称"本次 发行并上市"）的申请，并于同日在香港联交所网站刊登了本次发行并上市的申请资料。该申请资料为 公司按照香港证券及期货事务监察委员会（以下简称"香港证监会"）及香港联交所的要求编制和刊发， 为草拟版本，其所载资料可能会适时作出更新及修订，投资者不应根据其中的资料作出任何投资决定。 鉴于本次发行并上市的认购对象仅限于符合相关条件的境外投资者及依据中国相关法律法规有权进行境 外证券投资的境内合格投资者，公司将不会在境内证券交易所的网站和符合境内监管机构规定条件的媒 体上刊登该申请资料，但为使境内投资者及时了解该等申请资料披露的本次发行并上市以及公司的其他 相关信息，现提供该申请资料在香港联交所网站的查询链接供查阅： 中文： 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗漏。 浙江京新药业股份有限公司 董事会 2026年2月12日 http ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 登录新浪财经APP 搜索【信披】查看更多考评等级 近日，湖北广济药业股份有限公司（以下简称"公司"）收到国家药品监 督管理局核准签发的甲钴胺片的《药品注册证书》。现将相关情况公告如下： 一、基本情况 1.药品通用名称：甲钴胺片 2.受理号：CYHS2402791 3.证书编号：2026S00402 4.剂型：片剂 5.包装规格：10片/板×2板/盒 6.注册分类：化学药品4类 7.药品注册标准编号：YBH01362026 8.上市许可持有人名称：湖北广济药业股份有限公司 地址：湖北省黄冈武穴市大金广济药业生物产业园A区 10.审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注册的有关要 求，批准注册，发给药品注册证书。质量标准、说明书、标签及生产工艺照所附执行。药品生产企业应 当符合药品生产质量管理规范要求方可生产销售。 11.药品批准文号：国药准字H20263341 二、药品的其他相关情况 甲钴胺片主要适用于周围神经病的治疗。 三、对公司的影响 本次甲钴胺片《药品注册证书》的获批，标志 ...

Financial Performance Announcement - The company, BeiGene, has announced that it will release its financial results for the fourth quarter and full year of 2025 on February 26, 2026, after the Hong Kong Stock Exchange trading hours [1][2] - The board of directors will review and approve the financial results on the same day [2] - A conference call will be held on February 26, 2026, at 8:00 AM Eastern Time (9:00 PM Hong Kong Time) to discuss the results, which will be available for investors to participate via the company's website [2] - The company expects to publish its audited annual results for 2025 by March 31, 2026, or earlier, in accordance with Hong Kong listing rules [2]

Core Viewpoint - The recent round of national drug procurement has resulted in 4,163 products from 1,020 companies being shortlisted, covering 316 commonly used drugs across 26 therapeutic areas, with only 21 original drugs selected, representing less than 10% of the total [1][2]. Group 1: Procurement Details - The procurement aims to reduce drug prices and patient burdens while reallocating saved healthcare funds to innovative drugs [2]. - The procurement process involved 51,000 medical institutions, with a high selection rate of 93% and an average of 14 companies selected per product [2][3]. - The results of this procurement are expected to be implemented by the end of March 2026, with a procurement cycle lasting until the end of 2028 [2]. Group 2: Original Drug Participation - The selected original drugs include various formulations from companies like Bristol-Myers Squibb, Sanofi, and Bayer, with some previously shortlisted in earlier rounds [3]. - Notable original drugs that did not participate in this round include AstraZeneca's gefitinib and Sanofi's clopidogrel, which had previously been selected [4][3]. Group 3: Market Dynamics - The phenomenon known as "patent cliff" has led to significant declines in sales and profits for original drugs post-patent expiration, making it challenging for them to maintain market share without substantial price reductions [6]. - Some original drug companies have reduced or dissolved their sales teams for products affected by procurement policies, yet many still find market opportunities outside public hospital procurement [7]. - Cross-national pharmaceutical companies are increasingly focusing on innovative drug development while divesting mature product lines to local firms [8][9].

Core Viewpoint - The company, Honghua Medical (00013), is set to experience several key events in 2026, including annual performance releases and significant new drug development progress [1]. Financial Performance - The company plans to hold a board meeting on March 5, 2026, to review and approve the annual performance for the year ending December 31, 2025 [2]. Business Development - The Phase III study of the novel spleen tyrosine kinase inhibitor, Solipinib, for the treatment of warm antibody autoimmune hemolytic anemia has met its primary endpoint. The company plans to submit a new drug application to the National Medical Products Administration of China in the first half of 2026 [3]. Product Development Progress - The company's antibody-drug conjugate platform candidates, HMPL-A580 and HMPL-A830, are expected to initiate Phase I clinical trials in 2026. Additionally, recent pipeline advancements include the acceptance and priority review of new drug applications for Vanregatinib and Savolitinib [4].

and the Dak this i S 1 19 The Property 77 hand of the ...

2025年全市新设经营主体38.01万户、同比增长20.7%，新设科技型企业15.25万户、占新设企业的 47.49%，全社会研发经费投入强度稳定在6%左右…… 厚植沃土，才能活力迸发。近日，《北京市营商环境发展报告（2025）》发布。报告披露，本市在严格 依法的前提下采取"轻微免罚""首违不罚"，全市免罚慎罚事项已达1000余项，让执法更有温度。 "一件事"整体压缩办事时限58% 定期交流培训、分享风险案例、根据特定业务场景给出合规策略建议……去年，北京首批助企合规发展 服务站挂牌成立，面向平台企业"一站式"提供常态化合规指导服务。 "北京在全国首创平台企业助企合规发展服务站、合规评价机制及平台主体全景画像，让企业可以在源 头减少问题的发生。"市发改委相关负责人说。在另一头，北京还强化公平竞争审查刚性约束，实现审 查制度市、区全覆盖，抽查各类政策措施1000件。 一家企业的成长和日常经营涉及方方面面。为此，北京以全周期服务体系提质升级回应企业需求—— 惠企政策更快落地："京策"平台汇聚2025年新发布政策1805份，上线政策兑现事项1112个，更多"免申 即享""直达快享"政策推出。 企业诉求更好解决：12 ...

Summary of Edgewise Therapeutics Conference Call Company Overview - **Company**: Edgewise Therapeutics (NasdaqGS:EWTX) - **Event**: 2026 Healthcare Innovation Conference - **Key Speaker**: Behrad Derakhshan, Chief Operating Officer Key Points Industry and Product Focus - Edgewise is focused on developing treatments for hypertrophic cardiomyopathy (HCM) and Becker muscular dystrophy, with significant unmet needs in these areas [5][6] - The company is preparing for a Phase 3 readout in its Becker program with sevasemten, aiming to launch the first drug for Becker patients [5] Clinical Trials and Data - The company is excited about the upcoming Part D data related to obstructive and non-obstructive HCM, emphasizing the rigorous data quality over competitor timelines [16][17] - Changes in screening criteria for clinical trials have been implemented to reduce AFib observations, including extending the look-back period for patient history and enhancing cardiac monitoring [11][12][13] - The company reported no AFib burden during extensive screening, indicating progress in addressing previous concerns [13] Competitive Landscape - Edgewise aims to differentiate its drug by allowing physicians to dose optimize without the need for rigorous echo monitoring, which is a limitation for current treatments [26][27][36] - The company believes there is still room for improvement in the obstructive population, particularly outside of centers of excellence where community physicians manage heart failure [24][25] Future Plans and Regulatory Considerations - Edgewise plans to initiate Phase 3 trials in the fourth quarter of 2026 and is preparing to engage with the FDA regarding registration studies [46][49] - The company is considering the potential for a synergistic use of its drug with current treatments in the obstructive setting, although it may lead to a switch rather than combination therapy [47] Commercial Strategy - Edgewise is building a commercial organization in anticipation of positive data, aiming for a broad label to treat patients diagnosed during adolescence [60][62] - The company is focused on demonstrating the long-term benefits of its drug to justify orphan drug pricing and ensure patient retention [59][60] Other Programs - The company is also advancing EDG-15400, with data expected in the second quarter of 2026, targeting heart failure with preserved ejection fraction (HFpEF) [48][49] - The Grand Canyon study for sevasemten is on track, with a low dropout rate indicating strong patient retention [53][54] Market Positioning - Edgewise is positioning itself to capture a significant market share in HCM and Becker muscular dystrophy by addressing unmet needs and simplifying treatment protocols for physicians [38][60] Conclusion - Edgewise Therapeutics is poised for significant developments in the coming year, with a focus on rigorous data quality, innovative treatment approaches, and a strong commercial strategy to meet the needs of patients with HCM and Becker muscular dystrophy [5][6][60]